Search - tctmd.com

Displaying 221 - 240 of 449

Sort: Relevancy | Date

News Conference News ESC 2017

CANTOS: Anti-inflammatory Agent Canakinumab Modestly Reduces Major CVD Events

Michael O'Riordan

August 27, 2017

News Daily News

Early Invasive Strategy Benefits Select High-Risk NSTE ACS Patients, Meta-analysis Suggests

Michael O'Riordan

August 14, 2017

News Daily News

Money-Back Guarantee for Evolocumab Has Little Impact on Cost-Effectiveness

Michael O'Riordan

August 08, 2017

News Daily News

‘Remnant’ Cholesterol Linked With CVD Risk, Even When LDL Levels Are Low

Michael O'Riordan

August 01, 2017

News Conference News EuroPCR 2017

Best Antiplatelet Therapy in Real-World PCI? European Registries Fuel the Debate

Caitlin E. Cox

May 22, 2017

Presentation EuroPCR 2017

Safety of Coronary Revascularisation Deferral Based on iFR and FFR Measurements in Stable Angina and Acute Coronary Syndromes

Presenter: Javier Escaned

May 17, 2017

News Conference News EuroPCR 2017

DESSOLVE III: MiStent Holds Up Well Against Xience at 12 Months, Hints at Potential Longer-Term Benefit

Michael O'Riordan

May 16, 2017

News Conference News EuroPCR 2017

EuroPCR 2017: New Stents, New Questions for PCI Today and Tomorrow as Angioplasty Turns 40

Shelley Wood

May 12, 2017

News Daily News

Younger, Heavier, and Uninsured: Trends Point to Rising Risks in Acute MI, Ischemic Stroke Patients

Yael L. Maxwell

April 11, 2017

News Daily News

ICTUS: No Benefit at 10 Years With Early Invasive Strategy in NSTE ACS Patients

Michael O'Riordan

April 11, 2017

News Daily News

Scaffold Thrombosis Concerns With Absorb BVS Echoed in AIDA Trial

Michael O'Riordan

March 29, 2017

News Conference News ACC 2017

FFR-Guided Complete Revascularization Tops PCI of Culprit Artery Alone in Acute STEMI

Todd Neale

March 18, 2017

News Conference News ACC 2017

iFR Matches FFR for Clinical Outcomes in Patients With Intermediate Lesions

Caitlin E. Cox

March 18, 2017

News Conference News ACC 2017

Replacing Aspirin With Low-Dose Rivaroxaban for Post-ACS Therapy Appears Safe

Todd Neale

March 18, 2017

News Conference News ACC 2017

FOURIER: Evolocumab Reduces Risk of CVD Events by 15% Compared With Placebo

Michael O'Riordan

March 17, 2017

News Conference News ACC 2017

ACC 2017: CVD Outcomes for Evolocumab, Intermediate-Risk TAVR, Coronary Physiology Tests, and More

Shelley Wood

March 10, 2017

News Conference News ACC 2017

Erectile Dysfunction Meds Linked to Fewer Death and HF Hospitalizations After MI

L.A. McKeown

March 09, 2017

News Daily News

‘Misalignment’ Exists Between What Concerns Patients and Physicians Most After PCI

Michael O'Riordan

February 13, 2017

$The Coronary Sinus Reducer: A Device Based Therapy for Refractory Angina$

Presentation JIM 2017

The Coronary Sinus Reducer: A Device Based Therapy for Refractory Angina

Presenter: Francesco Giannini

February 10, 2017

News Daily News

Minding the Gaps: Race and Sex Disparities in Rehospitalization Post-MI Might Be Due to Angina, Depression

Yael L. Maxwell

February 10, 2017

Advertisement

CANTOS: Anti-inflammatory Agent Canakinumab Modestly Reduces Major CVD Events

Early Invasive Strategy Benefits Select High-Risk NSTE ACS Patients, Meta-analysis Suggests

Money-Back Guarantee for Evolocumab Has Little Impact on Cost-Effectiveness

‘Remnant’ Cholesterol Linked With CVD Risk, Even When LDL Levels Are Low

Best Antiplatelet Therapy in Real-World PCI? European Registries Fuel the Debate

Safety of Coronary Revascularisation Deferral Based on iFR and FFR Measurements in Stable Angina and Acute Coronary Syndromes

DESSOLVE III: MiStent Holds Up Well Against Xience at 12 Months, Hints at Potential Longer-Term Benefit

EuroPCR 2017: New Stents, New Questions for PCI Today and Tomorrow as Angioplasty Turns 40

Younger, Heavier, and Uninsured: Trends Point to Rising Risks in Acute MI, Ischemic Stroke Patients

ICTUS: No Benefit at 10 Years With Early Invasive Strategy in NSTE ACS Patients

Scaffold Thrombosis Concerns With Absorb BVS Echoed in AIDA Trial

FFR-Guided Complete Revascularization Tops PCI of Culprit Artery Alone in Acute STEMI

iFR Matches FFR for Clinical Outcomes in Patients With Intermediate Lesions

Replacing Aspirin With Low-Dose Rivaroxaban for Post-ACS Therapy Appears Safe

FOURIER: Evolocumab Reduces Risk of CVD Events by 15% Compared With Placebo

ACC 2017: CVD Outcomes for Evolocumab, Intermediate-Risk TAVR, Coronary Physiology Tests, and More

Erectile Dysfunction Meds Linked to Fewer Death and HF Hospitalizations After MI

‘Misalignment’ Exists Between What Concerns Patients and Physicians Most After PCI

The Coronary Sinus Reducer: A Device Based Therapy for Refractory Angina

Minding the Gaps: Race and Sex Disparities in Rehospitalization Post-MI Might Be Due to Angina, Depression

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content